EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly

İmdat Eroğlu iD, Burcin Gonul Iremli iD, Ilkay S Idilman iD, Deniz Yuce iD, Incilay Lay iD, Deniz Akata iD, Tomris Erbas iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von İmdat Eroğlu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hacettepe University, School of Medicine, 06230, Ankara, Turkey. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Insulin Resistance, Acromegaly. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hacettepe University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Nonalcoholic fatty liver disease (NAFLD) is a metabolical disorder and can lead to liver fibrosis. Because it is commonly seen, several noninvasive scores (NS) have been validated to identify high-risk patients. Patients with NAFLD have been shown to have higher serum angiopoietin-like protein-8 (ANGPTL-8) levels.

Objective

The risk of NAFLD is known insufficiently in acromegaly. Moreover, the utility of the NS and the link between NAFLD and ANGPTL-8 in acromegaly is unknown.

Methods

Thirty-two patients with acromegaly (n = 15, active [AA] and n = 17, controlled acromegaly [CA]) and 19 healthy controls were included. Magnetic resonance imaging (MRI)-proton density fat fraction (PDFF) was used to evaluate hepatic steatosis, and magnetic resonance elastography to evaluate liver stiffness measurement. ANGPTL-8 levels were measured with ELISA.

Results

Median liver MRI-PDFF and NAFLD prevalence in AA were lower than in CA (P = .026 and P < .001, respectively). Median magnetic resonance elastography-liver stiffness measurement were similar across groups. Of the NS, visceral adiposity index, fatty liver index, hepatic steatosis index, and triglyceride-glucose index (TyG) all showed positive correlation with the liver MRI-PDFF in the control group. However, only TyG significantly correlated with liver fat in the AA and CA groups. There was no correlation between traditional NAFLD risk factors (body mass index, waist circumference, C-reactive protein, homeostasis model assessment for insulin resistance, visceral adipose tissue) and liver MRI-PDFF in the AA and CA. Patients with acromegaly with NAFLD had lower GH, IGF-1, and ANGPTL-8 levels than in those without NAFLD (P = .025, P = .011, and P = .036, respectively).

Conclusion

Active acromegaly may protect from NAFLD because of high GH. In patients with acromegaly, NAFLD risk cannot be explained with classical risk factors; hence, additional risk factors must be identified. TyG is the best score to evaluate NAFLD risk. Lower ANGPTL-8 in patients with acromegaly and NAFLD implies this hormone may be raised because of insulin resistance rather than being a cause for NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseInsulin ResistanceAcromegalyHumansLiverLiver CirrhosisMagnetic Resonance ImagingTriglycerides

Stichwörter der Autor:innen

ANGPTL-8MRE-LSMMRI-PDFFNAFLDacromegalygrowth hormonenoninasive scores

Substanzen

Triglycerides

Autor:innen und Institutionen

  • Department of Internal Medicine, Hacettepe University, School of Medicine, 06230, Ankara, Turkey.
  • Department of Endocrinology and Metabolism, Hacettepe University, School of Medicine, 06230, Ankara, Turkey.
  • Department of Radiology, Hacettepe University, School of Medicine, 06230, Ankara, Turkey.
  • Department of Preventive Oncology, Hacettepe University, School of Medicine, 06230, Ankara, Turkey.
  • Department of Biochemistry, Hacettepe University, School of Medicine, 06230, Ankara, Turkey.

ORCID-Profile: İmdat Eroğlu, Burcin Gonul Iremli, Ilkay S Idilman, Deniz Yuce, Incilay Lay, Deniz Akata, Tomris Erbas

Förderung

  • Hacettepe University

Zitieren

APA

Eroğlu, İ., Iremli, B. G., Idilman, I. S., Yuce, D., Lay, I., Akata, D., & Erbas, T. (2023). Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad490

Vancouver

Eroğlu İ, Iremli BG, Idilman IS, Yuce D, Lay I, Akata D, et al. Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad490

BibTeX
@article{Erolu2023,
  author = {Eroğlu, İmdat and Iremli, Burcin Gonul and Idilman, Ilkay S and Yuce, Deniz and Lay, Incilay and Akata, Deniz and Erbas, Tomris},
  title = {Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad490}
}
Kostenlos starten →